The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study
Abstract
Background—: Uncertainty remains over optimal antithrombotic treatment of patients with atrial fibrillation presenting with myocardial infarction and/or undergoing percutaneous coronary intervention. We investigated the risk and time frame for bleeding following myocardial infarction/percutaneous coronary intervention in patients with atrial fibrillation according to antithrombotic treatment. Methods and Results—: Patients with atrial fibrillation and admitted with myocardial infarction or for percutaneous coronary intervention between 2000 and 2009 (11 480 subjects, mean age 75.6 years [SD ±10.3], males 60.9%) were identified by individual level linkage of nationwide registries in Denmark. Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel. We calculated crude incidence rates and adjusted hazard ratios by Cox regression models. Within 1 year, 728 bleeding events were recorded (6.3%); 79 were fatal (0.7%). Within 30 days, rates were 22.6, 20.3, and 14.3 bleeding events per 100 person-years for TT, VKA+antiplatelet, and dual antiplatelet therapy, respectively. Both early (within 90 days) and delayed (90–360 days) bleeding risk with TT exposure in relation to VKA+antiplatelet was increased; hazard ratio 1.47 (1.04;2.08) and 1.36 (0.95;1.95), respectively. No significant difference in thromboembolic risk was observed for TT versus VKA+antiplatelet; hazard ratio, 1.15 (0.95;1.40). Conclusions—: High risk of bleeding is immediately evident with TT after myocardial infarction/percutaneous coronary intervention in patients with atrial fibrillation. A continually elevated risk associated with TT indicates no safe therapeutic window, and TT should only be prescribed after thorough bleeding risk assessment of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Approximately 15% of AF patients in contemporary trials 513 and registries [514][515][516] have a history of myocardial 1498 infarction.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [515]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855
Ruiz-Nodar, J. M., Marín, F., Hurtado, J. A., Valencia, J., Pinar, E., Pineda, J., Gimeno, J. R., Sogorb, F., Valdés, M., & Lip, G. Y. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.035 · Cited by 269 · cited 1×
“of total bleeding ( fatal events ) / person years at risk Triple therapy VKA + antiplatelet therapy Dual antiplatelet therap y VKA monotherapy Single antiplatelet therapy 27 ( 1) / 119 30 ( 2) / 148 37 ( 1) / 259 5 ( 1) / 59 48 ( 11) / 309 39 ( 0) / 193 38 ( 3) / 291 40 ( 2) / 596 9 ( 0) / 104 54 (12) / 561 21 ( 3) /…”
Research works printed but not linked: 27
- 10.1160/TH09-08-0580 · DOI
- 10.1161/CIRCINTERVENTIONS.111.965186 · DOI
- 10.1159/000086918 · DOI
- 10.1016/S0140-6736(09)61751-7 · DOI
- 10.1161/CIRCULATIONAHA.106.612812 · DOI
- 10.1093/europace/eur126 · DOI
- 10.1093/eurheartj/ehr204 · DOI
- 10.1080/07853890802089786 · DOI
- 10.1002/ccd.20733 · DOI
- 10.1016/j.ahj.2003.06.004 · DOI
- 10.1136/bmj.d124 · DOI · Paper page
- 10.1016/j.ejheart.2008.05.006 · DOI
- 10.1111/j.1538-7836.2011.04378.x · DOI
- 10.1002/pds.2109 · DOI
- 10.1016/j.jcin.2007.11.004 · DOI
- 10.1093/eurheartj/ehi485 · DOI
- 10.1161/CIRCULATIONAHA.109.924944 · DOI
- 10.1093/eurheartj/ehm186 · DOI
- 10.1056/NEJMoa1105819 · DOI
- 10.1056/NEJMoa1112277 · DOI
- 10.1001/archinte.167.1.68 · DOI
- 10.1159/000102143 · DOI
- 10.1161/CIRCULATIONAHA.105.547844 · DOI
- 10.1016/S0895-4356(02)00591-7 · DOI · Paper page
- 10.1111/j.1540-8183.2011.00683.x · DOI
- 10.1093/eurheartj/ehi505 · DOI
- 10.1016/S0140-6736(10)61194-4 · DOI
Cited by
Sorted by citations
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,439
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P. H., Windecker, S., Alfonso, F., Collet, J., Cremer, J., Falk, V., Filippatos, G. S., Hamm, C. W., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,217
Metadata
- Authors
- Lamberts, M., Olesen, J. B., Ruwald, M. H., Hansen, C. M., Karasoy, D., Kristensen, S. L., Køber, L., Torp-Pedersen, C., Gislason, G. H., & Hansen, M. L.
- Affiliations
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- ORCID
- Venue
- Circulation
- Published
- 2012-09-04
- Volume
- 126
- Issue
- 10
- Pages
- 1185-1193
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2108659563
- Cited by
- 413
- References
- 0
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 9 · 2023: 10 · 2022: 16 · 2021: 24 · 2020: 36 · 2019: 42 · 2018: 42 · 2017: 43 · 2016: 37 · 2015: 40 · 2014: 41 · 2013: 53 · 2012: 6
- FWCI
- 28.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- atrial fibrillation, bleeding risk, triple therapy, vitamin K antagonists, clopidogrel, aspirin, antiplatelet therapy, dual antiplatelet therapy, myocardial infarction, percutaneous coronary intervention, thromboembolic risk, bleeding risk assessment
- MeSH terms
- Clopidogrel, Aged, Aged, 80 and over, Aspirin, Atrial Fibrillation, Denmark, Drug Therapy, Combination, Female, Fibrinolytic Agents, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Registries, Risk Factors, Ticlopidine, Vitamin K, Cohort Studies, Comorbidity, Angioplasty, Balloon, Coronary, Stroke, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
